Large intestine

EQS-News: Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

Retrieved on: 
Tuesday, August 1, 2023
Partnership, CRC, Polymerase, Collaborative partnership, Survival, Cancer, Large intestine, Organization, Colorectal cancer, Death, Patient, Ageing, Massive parallel sequencing, PCR, Vaccine, Pharmaceutical industry, NGS

Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.

Key Points: 
  • Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.
  • Colorectal cancer remains a critical health concern, with approximately 43,000 diagnoses and 16,800 deaths occurring each year in the UK alone.
  • Mainz Biomed is delighted to collaborate with Marylebone Laboratory, which recently expanded its presence in London, under the Marylebone Diagnostic Centre brand where it provides a comprehensive range of screening and diagnostic testing services.
  • Marylebone Laboratory brings extensive expertise in NGS (Next-Generation Sequencing) and PCR (Polymerase Chain Reaction)-based molecular genetic testing.

Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

Retrieved on: 
Tuesday, August 1, 2023
Partnership, CRC, Polymerase, Survival, Cancer, Large intestine, Organization, Colorectal cancer, Death, Patient, Ageing, Massive parallel sequencing, PCR, Pharmaceutical industry, Vaccine, NGS

Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.

Key Points: 
  • Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.
  • Colorectal cancer remains a critical health concern, with approximately 43,000 diagnoses and 16,800 deaths occurring each year in the UK alone.
  • Mainz Biomed is delighted to collaborate with Marylebone Laboratory, which recently expanded its presence in London under the Marylebone Diagnostic Centre brand, where it provides a comprehensive range of screening and diagnostic testing services.
  • Marylebone Laboratory brings extensive expertise in NGS (Next-Generation Sequencing) and PCR (Polymerase Chain Reaction)-based molecular genetic testing.

Statement from the Prevent Cancer Foundation on updated guidance for colorectal cancer screening from the American College of Physicians

Retrieved on: 
Monday, July 31, 2023
Bleeding, Prevent Cancer Foundation, National Colon Cancer Awareness Month, Fear, Cancer, Large intestine, Risk, Perforated ulcer, Organization, Incidence, Colorectal cancer, National Cancer Institute, Patient, American College of Gastroenterology, Colonoscopy, Confusion, Mortality, American Cancer Society, Transport, American College, NCI, American College of Physicians, ACP, USPSTF, Dietary supplement, Medical imaging, Dairy

Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.

Key Points: 
  • Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.
  • The Prevent Cancer Foundation strongly opposes the updated guidance, which goes against the latest evidence-based screening recommendations from the organizations working in the cancer screening space every day.
  • The Prevent Cancer Foundation supports following the guidelines of the USPSTF, the American Cancer Society and American College of Gastroenterology and encourages all adults of average risk to begin colorectal cancer screening at age 45.
  • There are several options available for colorectal cancer screening, and all available colorectal cancer screening methods are safe and can save lives.

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Retrieved on: 
Monday, July 10, 2023
MYC, Therapy, Cancer, Research, Large intestine, RNA, RMA, Doctor of Philosophy, Colorectal cancer, Rare, Vaccine

WATERTOWN, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that Cancer Research Communications has published “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer”. The publication demonstrates the potential of Eloxx’s TURBO-ZM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) and details preclinical data that demonstrate activity for ZKN-157 against subtypes of colorectal cancer.

Key Points: 
  • The publication demonstrates the potential of Eloxx’s TURBO-ZM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) and details preclinical data that demonstrate activity for ZKN-157 against subtypes of colorectal cancer.
  • “We are incredibly pleased with this publication, as it highlights the power of our TURBO-ZM platform to target the human ribosome to develop new potential therapeutics.
  • Importantly, for the first time, we also demonstrate that MYC overexpressing cancers can be targeted by exploiting ribosome heterogeneity, as ZKN-157, a novel RMA, demonstrated activity against subtypes of colorectal cancer,” said Vijay Modur MD, PhD, Head of R&D of Eloxx.
  • ZKN-157 was designed to selectively target the consensus molecular subtype 2 (CMS2) of colorectal cancer, which is distinguished by high MYC activity.

Devyser Launches Two New Genetic Testing Solutions for Hereditary Cancer

Retrieved on: 
Thursday, June 29, 2023
DNA, Genetics, Workflow, NGS, Hereditary nonpolyposis colorectal cancer, PMS2, Cancer, Breast, Large intestine, Colorectal cancer, Risk, Blood, Genetic testing, BRCA2, Gene, Breast cancer, Software, Online shopping, Vaccine, Pharmaceutical industry

Devyser LynchFAP provides a comprehensive solution to analyze PMS2 and 9 other genes associated with hereditary colorectal cancer syndromes.

Key Points: 
  • Devyser LynchFAP provides a comprehensive solution to analyze PMS2 and 9 other genes associated with hereditary colorectal cancer syndromes.
  • Devyser LynchFAP is designed to overcome one of the greatest challenges for Lynch syndrome genetic testing - the localization of genetic variants to PMS2 and its pseudogene PMS2CL.
  • Having a hereditary cancer syndrome significantly increases an individual's risk of developing colorectal cancer, among multiple other cancer types.
  • "These genetic testing solutions represent a significant advancement in our hereditary cancer offering.

Devyser Launches Two New Genetic Testing Solutions for Hereditary Cancer

Retrieved on: 
Thursday, June 29, 2023
DNA, Genetics, Workflow, NGS, Hereditary nonpolyposis colorectal cancer, PMS2, Cancer, Breast, Large intestine, Colorectal cancer, Risk, Blood, Genetic testing, BRCA2, Gene, Breast cancer, Software, Online shopping, Vaccine, Pharmaceutical industry

Devyser LynchFAP provides a comprehensive solution to analyze PMS2 and 9 other genes associated with hereditary colorectal cancer syndromes.

Key Points: 
  • Devyser LynchFAP provides a comprehensive solution to analyze PMS2 and 9 other genes associated with hereditary colorectal cancer syndromes.
  • Devyser LynchFAP is designed to overcome one of the greatest challenges for Lynch syndrome genetic testing - the localization of genetic variants to PMS2 and its pseudogene PMS2CL.
  • Having a hereditary cancer syndrome significantly increases an individual's risk of developing colorectal cancer, among multiple other cancer types.
  • "These genetic testing solutions represent a significant advancement in our hereditary cancer offering.

Global Colorectal Cancer Screening Market to 2033: Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 28, 2023
Health, Oncology, DNA, Intellectual property, Partnership, University, CRC, Face, Epigenomics AG, Cancer, Instituto Nacional de Medicina Genómica, Large intestine, MD Anderson Cancer Center, Genomics, Biomarker, Incidence, Helmy Eltoukhy, Patent, Colorectal cancer, Epigenomics, Growth, Region, Dairy, Pharmaceutical industry

The global colorectal cancer screening market is projected to reach $9.73 billion by 2033 from $1.93 billion in 2022, growing at a CAGR of 15.94% during the forecast period 2023-2033.

Key Points: 
  • The global colorectal cancer screening market is projected to reach $9.73 billion by 2033 from $1.93 billion in 2022, growing at a CAGR of 15.94% during the forecast period 2023-2033.
  • The growth in the global colorectal cancer screening market is expected to be driven by the rising incidence of colorectal cancer and the increasing financial burden on healthcare, advances in genomics and molecular diagnostics, and the growing demand for non-invasive testing for colorectal cancer.
  • In March 2023, Guardant Health collaborated with the Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence.
  • The following are the drivers for the global colorectal cancer screening market:
    The market is expected to face some limitations as well due to the following restraints:
    Clinical Genomics Technologies Pty Ltd.

Medtronic Recognized for Artificial Intelligence Innovation in 2023 AI Breakthrough Awards Program

Retrieved on: 
Wednesday, June 21, 2023
Natural language processing, Artificial Intelligence for IT Operations, Deep learning, Synthetic media, Eye, Cancer, Intelligence, Gastroenterology, Large intestine, Endoscopy, Computer vision, Colorectal cancer, Death, Data, Physician, Polyp (medicine), Machine learning, Algorithm, Robotics, Generative, Colonoscopy, Artificial intelligence, AI, FDA, GI, Cade, Polyp, Software, Medical device, Mobile phone, Medtronic

LOS ANGELES, June 21, 2023 /PRNewswire-PRWeb/ -- AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market, today announced that Medtronic plc, the leading global healthcare technology company, has been selected as winner of the "Best Deep Learning Platform" award in the sixth annual AI Breakthrough Awards program, recognizing the breakthrough innovation of Medtronic's GI Genius™ system.

Key Points: 
  • LOS ANGELES, June 21, 2023 /PRNewswire-PRWeb/ -- AI Breakthrough , a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market, today announced that Medtronic plc , the leading global healthcare technology company, has been selected as winner of the "Best Deep Learning Platform" award in the sixth annual AI Breakthrough Awards program, recognizing the breakthrough innovation of Medtronic's GI Genius™ system.
  • GI Genius is the first FDA authorized computer-aided detection (CADe) system using AI to help endoscopists identify colorectal polyps, regardless of shape, size, or morphology.
  • Our expanding AI capabilities at Medtronic create opportunities to deliver against unmet needs, including across the Gastrointestinal (GI) practice."
  • However, colonoscopy is difficult, and polyps may be difficult to find," said James Johnson, managing director, AI Breakthrough.

Pfizer Holds First MERA Precision Medicine Summit About Advancements in Cancer Treatment

Retrieved on: 
Tuesday, June 20, 2023
Laboratory, Pfizer, Genetics, Marie Cassidy, Personalized medicine, Arab world, Cancer, Lung cancer, Soybean oil, Large intestine, Liver cancer, Death, Colorectal cancer, Incidence, Patient, Medicine, Neoplasm, Health, MERA, World Health Organization, Pharmaceutical industry

JOHANNESBURG, June 20, 2023 /PRNewswire/ -- Pfizer conducted a discussion about the latest advances and breakthroughs in cancer care to improve patient lives in its first Middle East, Russia, and Africa (MERA) Precision Medicine Summit.

Key Points: 
  • JOHANNESBURG, June 20, 2023 /PRNewswire/ -- Pfizer conducted a discussion about the latest advances and breakthroughs in cancer care to improve patient lives in its first Middle East, Russia, and Africa (MERA) Precision Medicine Summit.
  • The event brought together more than 90 regional and international expert oncologists and pathologists to discuss the advances in precision medicine for cancer treatments.
  • To address this growing concern, Pfizer's MERA Precision Medicine Summit discussed the latest advancements in precision medicine.
  • Precision medicine customizes cancer treatment by analyzing a patient's genetics, tumor characteristics, and other factors.

Global Liver Metastases Treatment Market Report 2023: Sector is Expected to Reach $2.31 Billion by 2030 at a CAGR of 7.2% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 14, 2023
Health, Pharmaceutical, CCLM, Prevalence, Liver disease, Hospital, Cancer, Lung cancer, Large intestine, Colorectal cancer, Incidence, Developed country, Liver, Diagnosis, Breast cancer, Pharmaceutical industry, Medical imaging

The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030.

Key Points: 
  • The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030.
  • Whereas the incidence of breast cancer is expected to increase from 2.26 million in 2020 to 2.74 million in 2030.
  • In 2022, colorectal cancer dominated the liver metastases treatment market with a share of 40.55%.
  • By region, North America has a high revenue share in global liver metastases treatment market in 2022.